Willem Schaftenaar

Mr. Willem Schaftenaar


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2021 in Viruses
Verified
Journal Article
Open access
PDF file
THTabitha Elina Hoornweg
Tabitha Elina Hoornweg
WSWillem Schaftenaar
Willem Schaftenaar
GMGilles Maurer
Gilles Maurer
PDPetra B. van Den Doel
Petra B. van Den Doel
FMFieke Molenaar
Fieke Molenaar
CHCornelis De Haan
Cornelis De Haan
Elephant endotheliotropic herpesviruses (EEHVs) may cause acute, often lethal, hemorrhagic disease (EEHV-HD) in young elephants. Prevalence of EEHV in different elephant populations is still largely unknown. In order to improve diagnostic tools for the detection of EEHV infections and to obtain insight into its spread among elephants, we developed novel ELISAs based on EEHV1A gB and gH/gL. Performance of the ELISAs was assessed using sera from 41 European zoo elephants and 69 semi-captive elephants from Laos, one of the Asian elephant range countries. Sera from all (sub)adult animals tested (≥5 years of age) showed high reactivity with both gB and gH/gL, indicating that EEHV prevalence has been highly underestimated so far. Reactivity towards the antigens was generally lower for sera of juvenile animals (1 > 5 years). Only one (juvenile) animal, which was sampled directly after succumbing to EEHV-HD, was found to be seronegative for EEHV. The two other EEHV-HD cases tested showed low antibody levels, suggesting that all three cases died upon a primary EEHV infection. In conclusion, our study suggests that essentially all (semi-)captive (sub)adult elephants in European zoos and in Laos carry EEHV, and that young elephants with low antibody levels are at risk of dying from EEHV-HD.

22 July 2022 in Vaccine
Verified
Journal Article
Open access
JCJennifer Clinton
Jennifer Clinton
THTabitha Elina Hoornweg
Tabitha Elina Hoornweg
JTJie Tan
Jie Tan
RPRongsheng Peng
Rongsheng Peng
WSWillem Schaftenaar
Willem Schaftenaar
PLPaul D Ling
Paul D Ling
Asian elephants are an endangered species facing many threats, including severe hemorrhagic disease (HD) caused by the elephant endotheliotropic herpesvirus (EEHV). EEHV-HD is the leading cause of death in captive juvenile Asian elephants in North America and Europe, and also affects elephants in their natural range countries. Significant challenges exist for successful treatment of EEHV-HD, which include timely recognition of disease onset and limited availability of highly effective treatment options. To address this problem, our goal is to prevent lethal disease in young elephants by developing a vaccine that elicits robust and durable humoral and cell-mediated immunity against EEHV. EEHV glycoprotein B (gB) is a major target for cellular and humoral immunity in elephants previously exposed to EEHV. Therefore, we generated a vaccine containing recombinant EEHV1A gB together with a liposome formulated TLR-4 and saponin combination adjuvant (SLA-LSQ). CD-1 mice that received one or two vaccinations with the vaccine elicited significant anti-gB antibody and polyfunctional CD4+ and CD8+ T cell responses, while no adverse effects of vaccination were observed. Overall, our findings demonstrate that an adjuvanted gB protein subunit vaccine stimulates robust humoral and cell-mediated immune responses and supports its potential use in elephants.

23 August 2024 in Vaccine
Verified
Journal Article
Closed access
JCJennifer Clinton
Jennifer Clinton
THTabitha Elina Hoornweg
Tabitha Elina Hoornweg
JTJie Tan
Jie Tan
RPRongsheng Peng
Rongsheng Peng
WSWillem Schaftenaar
Willem Schaftenaar
PLPaul D Ling
Paul D Ling